Tigecycline: Microbiology, pharmacokinetics and clinical role for treatment of severe infections;Tigecyclin: Mikrobiologie, pharmakokinetik und klinischer stellenwert bei schweren infektionen

Chemotherapie Journal

Volumn 16, Issue 3, 2007, Pages 88-96

  Trautmann, Matthias ^a,b  

^a Klinikum Stuttgart ^*

^b KLINIKUM STUTTGART   (Germany)

Author keywords

Glycylcycline; Methicillin resistent Staphylococcus aureus (MRSA); Tetracyclines; Vancomycin resistent enterococci (VRE)

Indexed keywords

AZTREONAM; CHLORTETRACYCLINE; DOXYCYCLINE; GLYCYLCYCLINE DERIVATIVE; IMIPENEM; MINOCYCLINE; OXYTETRACYCLINE; ROLITETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ACINETOBACTER; ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; ENTEROBACTERIACEAE; ENTEROCOCCUS; GRAM NEGATIVE ANAEROBIC BACTERIA; GRAM POSITIVE BACTERIUM; GRAM POSITIVE COCCI; HUMAN; LOADING DRUG DOSE; LUNG INFECTION; SOFT TISSUE INFECTION; TREATMENT INDICATION;

EID: 34250856977     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Bergeron J, Ammirati M, Danley D, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)-and Tet(O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996;40:2226-8.
2. Betriu C, Rodriguez-Avial I, Sanchez BA, et al. In vitro acitivities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2002;46:892-5.
3. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis 2001;40:173-7.
4. Boucher HW, Wennosten CB, Moellering RC, et al. Studies on a glycyclcycline GAR-936. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA), USA.
5. Boucher HW, Wennersten CB, Eliopoulos GM. In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria. Antimicrob Agents Chemother 2000;44:2225-9.
6. Bronson JJ, Barrett FJ. Quinolone, everninomycin, glycylcycline, carbapenem, lipopeptide and cephem antibacterials in clinical development. Curr Med Chem 2001;8:1775-93.
7. Chopra I. Glycylcyclines: Third-generation tetracycline antibiotics. Curr Opin Pharmacol 2001;1:464-9.
8. Chopra I, Roberts M. Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 2001;65:232-60.
9. Conte JE, Golden JA, Kelly MG, Zurlinden E. Steady-state serum and intrapulmonary pharmacokinetics and pharmacodynamics of tigecycline. Int J Antimicrob Agents 2005;25:523-9.
10. Dartois N, on behalf of the tigecycline 305c SSI Study Group. Results of a phase 3, double-blind, safety and efficacy study comparing tigecycline with vancomycin/aztreonam to treat complicated skin and skin structure infections [abstract no. L-986]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington DC, USA.
11. Dartois N, Gioud-Paquet M, Ellis-Grosse EJ, et al. Tigecycline versus imipenem/cilastatin for treatment of complicated intraabdominal infections [abstract no. L-992c]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington DC, USA.
12. Dever LL, Shashikumar K, Johanson WG Jr. Antibiotics in the treatment of acute exacerbations of chronic bronchitis. Expert Opin Investig Drugs 2002;11:911-25.
13. Dimmling T, Vanderbeke O. Pharmakokinetik oral und intravenos verabreichbarer Tetracyclinpraparate. Med Klin 1975;70:279-85.
14. Dukart G, Dartois N, Cooper CA, Gandijini H. et al. Integrated results of 2 phase 3 studies comparing tigecycline with levofloxacin in patients with community-acquired pneumonia. ICAAC 2006, L-1450.
15. Edelstein PH, Weiss W, Edelstein M. Tigecycline (GAR-936) activity vs. Legionella in vitro, and in a cell and animal model of Legionaire's disease. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2002 Sep 26-30; San Diego (CA), USA.
16. Edlund C, Nord CE. In vitro susceptibility of anaerobic bacteria to GAR-936, a new glycylcycline. Clin Microbiol Infect 2000;6:159-63.
17. Eliopoulos GM, Wennersten CB, Cole G, et al. In vitro activities of two glycylcyclines against gram-positive bacteria. Antimicrob Agents Chemother 1994;38:534-41.
18. Fritsche TR, Sader HS, Stilwell MG, et al. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 2005;52:187-93.
19. Gales AC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. Diagn Microbiol Infect Dis 2000;36:19-36.
20. Goldstein EJ, Citron DM, Merriam CV, et al. Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens. Antimicrob Agents Chemother 2000;44:2747-51.
21. Hedberg M, Nord CE. In vitro activity of anaerobic bacteria to GAR-936, a new glycylcycline. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA), USA.
22. Henwood CJ, Geward T, Warner M, et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002;49:479-87.
23. Hoban DJ, Bellyou T, Polatnick L, et al. GAR-936 (GAR) demonstrates potent in vitro activity against multi-drug resistant Streptococcus pneumoniae (SPN). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago (IL), USA.
24. Hoellmann DB, Jacobs MR, Appelbaum PC. Antipneumococcal activity of GAR 936, a new glycylcycline, by agar dilution MIC. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA), USA.
25. Hoellmann DB, Pankuch GA, Jacobs MR, et al. Antipneumococcal activities of GAR-936 (a new glycylcycline) compared to those of nine other agents against penicillin-suspectible and -resistant pneumococci. Antimicrob Agents Chemother 2000;44:1085-8.
26. Hunter PA, Castaner J. GAR-936. Drugs Future 2001;26:851-8.
27. Johnson B, Bouchillon S, Stevens T, et al. Vancomycin-resistant enterococci (VRE) - a global problem: evaluation of tigecycline against recent isolates from multi-centers globally. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 13-16; Washington DC, USA. Abstract no. E-330.
28. Jones RN. Resistance patterns among nosocomial pathogens. Trends over the past few years. Chest 2001;119:397S-404S.
29. Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001;45:2604-8.
30. Lefort A, Lafaurie M, Massias L, et al. Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis. Antimicrob Agents Chemother 2003;47:216-22.
31. Kresken M, Brauers J, Peters G, Leitner E. Susceptibilities of three staphylococcal species to tigecycline and other drugs: results of the German T.E.S.T. (G.-T.E.S.T.) surveillance program 2005. ICAAC 2006; E-0751.
32. Livermore DM. The need for new antibiotics. Clin Microbiol Infect 2004;10(Suppl 4):1-9.
33. Mahalingam E, Trepeski L, Pong-Porter S, et al. In vitro activity of a new glycylcyline, GAR 936, against methicillin-resistant and -susceptible Staphylococcus aureus isolated in North America. 39th Interscience Conference; 1999 Sep 26-39; San Francisco (CA), USA.
34. Masuda M, Sakagawa E, Ohya S, et al. Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:2242-6.
35. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. Pharmacokinetic/ pharmacodynamic profile for tigecycline - a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005;52:165-71.
36. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41:S333-40.
37. Mikels SM, Brown AS, Breden L, et al. In vivo activities of GAR-936 (GAR), gentamicin (GEN), piperacillin (PIP) alone and in combination in a murine model of Pseudomonas aeruginosa pneumonia [abstract no. 414]. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sept 26-29; San Francisco (CA), USA.
38. Milatovic D, Fluit AC, Verhoef J. In vitro activity of GAR-936 against gram-positive and gram-negative bacteria. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Sep 22-25; Chicago (IL), USA.
39. Munoz-Price LS, Lolans K, Quinn JP. Four cases of invasive methicillin-resistant staphylococcus aureus (MRSA) infections treated with tigecycline. Scand J Infect Dis 2006;38:1081-4.
40. Murakami K; Tateda K, Musumoto T, et al. Efficacy of a novel tetracycline derivative, glycylcycline, against penicillin-resistant Streptococcus pneumoniae in a mouse model of pneumonia. J Antimicrob Chemother 2000;46:629-31.
41. Muralidharan G, Mojaverian P, Micalizzi M, et al. The effects of age and gender on the pharmacokinetics, safety, and tolerability of GAR-936, a novel glycylcycline antibiotic, in healthy subjects. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sept 17-20; Toronto, Canada.
42. Muralidharan G, Micalizzi M, Speth J, et al. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005;49: 220-9.
43. Murphy TM, Deitz JM, Petersen PJ, et al. Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis. Antimicrob Agents Chemother 2000;44:3022-7.
44. Murray J, Wilson S, Klein S, et al. The clinical response to tigecycline in the treatment of complicated intra-abdominal infections in hospitalized patients, a phase 2 clinical trial [abstract no. L-739]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sept 14-17; Chicago (Ill), USA.
45. Nannini EC, Pai SR, Singhh KV, et al. Activity of tigecycline (GAR-936), a novel glycylcycline, against enterococci in the mouse peritonitis model. Antimicrob Agents Chemother 2003;47:529-32.
46. Nathwani D. Tigecycline: clinical evidence and formulary positioning. Int J Antimicrob Agents 2005;25:185-92.
47. Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-80.
48. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004;38(Suppl 4):S341-5.
49. Petersen PJ, Jacobus NV, Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-7-butylglycylamido derivative of monocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-44.
50. Piper KE, Rouse MS, Wilson WR, et al. In vitro activity of GAR-936 against vancomycin resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant pneumococci. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto (Ontario), Canada.
51. Postier RG, Green SL, Klein SR, et al. Results of a multicenter, randomized, open-label efficacy ad safety study of two doses of tigecycline for complicated skin and skin structure infections in hospitalized patients. Clin Ther 2004;26:704-14.
52. Projan SJ. Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent. Pharmacotherapy 2000;20:219S-28S.
53. Rasmussen BA, Gluzman Y, Tally FP. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines. Antimicrob Agents Chemother 1994;38:1658-60.
54. Roblin PM, Hammerschlag MR. In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis. Int J Antimicrob Agents 2000;16:61-3.
55. Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, et al. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci 2005;50:634-9.
56. Rodvoid KA, Gotfried MH, Cwik M, et al. Tigecycline (TGC) concentrations (Cp) in lung tissue, cerebrospinal fluid (CSF), and bile of human subjects. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2005 Dec 13-16; Washington DC, USA. Abstract no. A-18.
57. Rubinstein E, Vaughan D. Tigecycline - a novel glycylcycline. Drugs 2005;65:1317-36.
58. Ruzin A, Keeney D, Bradford PA. AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii. An-timicrob Agents Chemother 2005;49:791-3.
59. Saner FH, Heuer M, Rath PM, et al. Successful salvage therapy with tigecycline after linezolid failure in a liver transplant recipient with MR-SA pneumonia. Liver Transpl 2006;12:1689-92.
60. Shonekan D, Handwerger S, Mildvan D. Comparative in vitro activities of RP59500 (quinupristin/dalfopristin), CL 329,998, CL 331,002, trovafloxacin, clinafloxacin, teicoplanin and vancomycin against gram-positive bacteria. J Antimicrob Chemother 1997;39:405-9.
61. + antiporter. Antimicrob Agents Chemother 1995;39:247-9.
62. Sum PE, Lee VJ, Testa RT, et al. Glycylcyclines, I: a new generation of potent antibacterial agents through modification of 9-aminotetracyclines. J Med Chem 1994;37:184-8.
63. Sum PE, Sum FW, Projan SJ. Recent developments in tetracycline antibiotics. Curr Pharm Des 1998;4:119-32.
64. Sum PE, Petersen P. Synthesis and structure-activity relationship of novel glycylcycline derivates leading to the discovery of GAR-936. Bioorg Med Chem Lett 1999;9:1459-62.
65. Sun HK, Ong CT, Umer A, et al. Pharmacokinetic profile of tigecycline in serum and skin blister fluid of healthy subjects after multiple intravenous administrations. Antimicrob Agents Chemother 2005;49:1629-32.
66. Taylor RS, Simpson IN. Review of treatment options for lyme borreliosis. J Chemother 2005;17(Suppl 2):3-16.
67. Tally FT, Ellestad GA, Testa RT. Glycylcyclines: a new generation of tetracyclines. J Antimicrob Chemother 1995;35:449-52.
68. Testa RT, Petersen PJ, Jacobus NV, et al. In vitro and in vivo antibacterial activities of the glycylcyclines, a new class of semisynthetic tetracyclines. Antimicrob Agents Chemother 1993;37:2270-7.
69. Tombs NI. Tissue distribution of GAR-936, a broad-spectrum antibiotic, in male rats. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26-29; San Francisco (CA), USA.
70. Troy SM, Muralidharan G, Micalizzi M, et al. The effects of renal disease on the pharmacokinetics of tigecycline (GAR-936). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL), USA.
71. van Ogtrop ML, Andes D, Stamstad TJ, et al. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various grampositive and gramnegative bacteria. Antimicrob Agents Chemother 2000;44:943-9.
72. Visalli MA, Murphy E, Projan SJ, Bradford PA. AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis. Antimicrob Agents Chemother 2003;47: 665-9.
73. Wexler HM, Molitoris E, Finegold SM. In vitro activities of two new glycylcyclines, N, N-dimethylglycylamido derivatives of minocyclines and 6-demethyl-6-deoxytetracycline, against 339 strains of anaerobic bacteria. Antimicrob Agents Chemother 1994;38:2513-5.
74. Wise R, Andrews JM. In vitro activities of two glycylcyclines. Antimicrob Agents Chemother 1994;38:1096-1102.
75. Zhanel GG, Homenuik K, Nichol K, et al. The glycylcyclines - a comparative review with the tetracyclines. Drugs 2004;64:63-88.
76. Zhanel GG, Karlowsky JA, Rubinstein E, et al. Tigecycline: a novel glycylcycline antibiotic. Exp Rev Anti Infect 2006;4:9-25.